A detailed history of Sargent Bickham Lagudis LLC transactions in Abbott Laboratories stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 52,584 shares of ABT stock, worth $5.99 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares
52,584
Previous 54,493 3.5%
Holding current value
$5.99 Million
Previous $5.27 Million 9.5%
% of portfolio
0.47%
Previous 0.47%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 23, 2023

SELL
$95.06 - $111.52 $181,469 - $212,891
-1,909 Reduced 3.5%
52,584 $0
Q3 2022

Oct 27, 2022

SELL
$96.76 - $112.03 $144,075 - $166,812
-1,489 Reduced 2.66%
54,493 $5.27 Million
Q2 2022

Jul 13, 2022

BUY
$102.07 - $123.37 $121,463 - $146,810
1,190 Added 2.17%
55,982 $6.08 Million
Q1 2022

Apr 27, 2022

BUY
$114.02 - $139.04 $215,953 - $263,341
1,894 Added 3.58%
54,792 $6.49 Million
Q4 2021

Jan 18, 2022

BUY
$115.53 - $141.46 $68,855 - $84,310
596 Added 1.14%
52,898 $7.45 Million
Q3 2021

Nov 05, 2021

BUY
$116.66 - $129.06 $12,832 - $14,196
110 Added 0.21%
52,302 $6.18 Million
Q2 2021

Jul 19, 2021

BUY
$105.79 - $124.53 $136,363 - $160,519
1,289 Added 2.53%
52,192 $6.05 Million
Q1 2021

May 24, 2021

BUY
$108.84 - $128.23 $80,541 - $94,890
740 Added 1.48%
50,903 $6.1 Million
Q4 2020

May 24, 2021

SELL
$105.0 - $114.42 $77,700 - $84,670
-740 Reduced 1.45%
50,163 $5.49 Million
Q4 2020

May 24, 2021

BUY
$105.0 - $114.42 $27,300 - $29,749
260 Added 0.51%
50,903 $6.1 Million
Q3 2020

Sep 01, 2021

SELL
$91.64 - $111.29 $12,096 - $14,690
-132 Reduced 0.26%
50,643 $5.51 Million
Q2 2020

Sep 07, 2021

BUY
$76.57 - $98.0 $119,678 - $153,174
1,563 Added 3.18%
50,775 $4.64 Million
Q1 2020

Sep 07, 2021

BUY
$62.82 - $91.86 $342,997 - $501,555
5,460 Added 12.48%
49,212 $3.88 Million
Q4 2019

Sep 14, 2021

BUY
$78.51 - $87.4 $43,416 - $48,332
553 Added 1.28%
43,752 $3.8 Million
Q3 2019

Sep 14, 2021

BUY
$81.84 - $88.74 $93,297 - $101,163
1,140 Added 2.71%
43,199 $3.61 Million
Q2 2019

Sep 13, 2021

BUY
$72.88 - $85.0 $115,441 - $134,640
1,584 Added 3.91%
42,059 $3.54 Million
Q1 2019

Sep 13, 2021

BUY
$66.22 - $80.06 $1.89 Million - $2.29 Million
28,585 Added 240.41%
40,475 $3.24 Million
Q4 2018

Sep 13, 2021

BUY
$65.56 - $74.27 $65 - $74
1 Added 0.01%
11,890 $860,000
Q3 2018

Sep 13, 2021

BUY
$60.81 - $73.36 $608 - $733
10 Added 0.08%
11,889 $872,000
Q2 2018

Sep 13, 2021

BUY
$57.57 - $63.54 $12,032 - $13,279
209 Added 1.79%
11,879 $725,000
Q1 2018

Sep 13, 2021

BUY
$56.27 - $63.62 $562 - $636
10 Added 0.09%
11,670 $699,000
Q4 2017

Sep 13, 2021

BUY
$53.68 - $57.47 $536 - $574
10 Added 0.09%
11,660 $665,000
Q3 2017

Sep 13, 2021

BUY
$48.06 - $53.64 $576 - $643
12 Added 0.1%
11,650 $622,000
Q2 2017

Sep 13, 2021

SELL
N/A
-74 Reduced 0.63%
11,638 $566,000
Q1 2017

Sep 13, 2021

BUY
N/A
11 Added 0.09%
11,712 $520,000
Q4 2016

Sep 13, 2021

BUY
N/A
260 Added 2.27%
11,701 $449,000
Q3 2016

Sep 13, 2021

BUY
N/A
404 Added 3.66%
11,441 $484,000
Q2 2016

Sep 07, 2021

BUY
N/A
505 Added 4.79%
11,037 $434,000
Q1 2016

Sep 07, 2021

BUY
N/A
10,532
10,532 $441,000

Others Institutions Holding ABT

About ABBOTT LABORATORIES


  • Ticker ABT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 1,751,219,968
  • Market Cap $199B
  • Description
  • Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for t...
More about ABT
Track This Portfolio

Track Sargent Bickham Lagudis LLC Portfolio

Follow Sargent Bickham Lagudis LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Bickham Lagudis LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Bickham Lagudis LLC with notifications on news.